Pharmacokinetic trial of three new rifaximin formulations for the treatment of gastrointestinal disorders.

Trial Profile

Pharmacokinetic trial of three new rifaximin formulations for the treatment of gastrointestinal disorders.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2013

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Crohn's disease; Inflammatory bowel diseases; Intestinal infections; Irritable bowel syndrome
  • Focus Pharmacokinetics
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2013 Status changed from recruiting to completed, based on information in a Salix Pharmaceuticals media release.
    • 28 Feb 2013 This study progressed during the fourth quarter of 2012, according to a Salix Pharmaceuticals media release.
    • 22 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top